Molecular models of NS3 protease variants of the Hepatitis C virus

da Silveira, Nelson J. F.; Arcuri, Helen A.; Bonalumi, Carlos E.; de Souza, Fátima P.; Mello, Isabel M. V. G. C.; Rahal, Paula; Pinho, João R. R.; de Azevedo Jr, Walter F.
January 2005
BMC Structural Biology;2005, Vol. 5, p1
Academic Journal
Background: Hepatitis C virus (HCV) currently infects approximately three percent of the world population. In view of the lack of vaccines against HCV, there is an urgent need for an efficient treatment of the disease by an effective antiviral drug. Rational drug design has not been the primary way for discovering major therapeutics. Nevertheless, there are reports of success in the development of inhibitor using a structure-based approach. One of the possible targets for drug development against HCV is the NS3 protease variants. Based on the three-dimensional structure of these variants we expect to identify new NS3 protease inhibitors. In order to speed up the modeling process all NS3 protease variant models were generated in a Beowulf cluster. The potential of the structural bioinformatics for development of new antiviral drugs is discussed. Results: The atomic coordinates of crystallographic structure 1CU1 and 1DY9 were used as starting model for modeling of the NS3 protease variant structures. The NS3 protease variant structures are composed of six subdomains, which occur in sequence along the polypeptide chain. The protease domain exhibits the dual beta-barrel fold that is common among members of the chymotrypsin serine protease family. The helicase domain contains two structurally related betaalpha-beta subdomains and a third subdomain of seven helices and three short beta strands. The latter domain is usually referred to as the helicase alpha-helical subdomain. The rmsd value of bond lengths and bond angles, the average G-factor and Verify 3D values are presented for NS3 protease variant structures. Conclusions: This project increases the certainty that homology modeling is an useful tool in structural biology and that it can be very valuable in annotating genome sequence information and contributing to structural and functional genomics from virus. The structural models will be used to guide future efforts in the structure-based drug design of a new generation of NS3 protease variants inhibitors. All models in the database are publicly accessible via our interactive website, providing us with large amount of structural models for use in protein-ligand docking analysis.


Related Articles

  • Antiviral drugs: Breakthrough for HCV research. Jones, Susan // Nature Reviews Drug Discovery;Aug2005, Vol. 4 Issue 8, p629 

    Reports on research on the replication of full-length hepatitis C virus (HCV) clones in vitro that pave the way for the development of effective antiviral therapies and vaccines. Differences from previous development of in vitro HCV replicon systems; Development of an in vitro system that...

  • Development of a plant-derived subunit vaccine candidate against hepatitis C virus. Nemchinov, L. G.; Liang, T. J.; Rifaat, M. M.; Mazyad, H. M.; Hadidi, A.; Keith, J. M. // Archives of Virology;Dec2000, Vol. 145 Issue 12, p2557 

    Summary. Hepatitis C virus (HCV) is a major cause of acute and chronic hepatitis with over 180 million cases worldwide. Vaccine development for HCV has been difficult. Presently, the virus cannot be grown in tissue culture and there is no vaccine or effective therapy against this virus. In this...

  • Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Shen, Lin; Peterson, Susan; Sedaghat, Ahmad R.; McMahon, Moira A.; Callender, Marc; Zhang, Haili; Zhou, Yan; Pitt, Eleanor; Anderson, Karen S.; Acosta, Edward P.; Siliciano, Robert F. // Nature Medicine;Jul2008, Vol. 14 Issue 7, p762 

    Highly active antiretroviral therapy (HAART) can control HIV-1 replication, but suboptimal treatment allows for the evolution of resistance and rebound viremia. A comparative measure of antiviral activity under clinically relevant conditions would guide drug development and the selection of...

  • Persistent Growth of a Human Plasma-Derived Hepatitis C Virus Genotype 1b Isolate in Cell Culture. Silberstein, Erica; Mihalik, Kathleen; Ulitzky, Laura; Plant, Ewan P.; Puig, Montserrat; Gagneten, Sara; Yu, Mei-ying W.; Kaushik-Basu, Neerja; Feinstone, Stephen M.; Taylor, Deborah R. // PLoS Pathogens;May2010, Vol. 6 Issue 5, p1 

    HCV (hepatitis C virus) research, including therapeutics and vaccine development, has been hampered by the lack of suitable tissue culture models. Development of cell culture systems for the growth of the most drug-resistant HCV genotype (1b) as well as natural isolates has remained a challenge....

  • Quasispecies Theory and the Behavior of RNA Viruses. Lauring, Adam S.; Andino, Raul // PLoS Pathogens;Jul2010, Vol. 6 Issue 7, p1 

    A large number of medically important viruses, including HIV, hepatitis C virus, and influenza, have RNA genomes. These viruses replicate with extremely high mutation rates and exhibit significant genetic diversity. This diversity allows a viral population to rapidly adapt to dynamic...

  • Prevalence of Production of Virus-Specific Interferon-γ among Seronegative Hepatitis C--Resistant Subjects Reporting Injection Drug Use. Freeman, Anthony J.; Ffrench, Rosemary A.; Post, Jeffrey J.; Harvey, Charles E.; Gilmour, Stuart J.; White, Peter A.; Marinos, George; Beek, Ingrid Van; Rawlinson, William D.; Lloyd, Andrew R. // Journal of Infectious Diseases;9/15/2004, Vol. 190 Issue 6, p1093 

    This report describes subjects who were highly likely to have been repeatedly exposed to hepatitis C virus (HCV) through injection drug use and who remained negative for anti-HCV antibody. Production of virus-specific interferon-γ by periph- eral blood mononuclear cells was seen in the...

  • Transduction of Human T Cells with a Novel T-Cell Receptor Confers Anti-HCV Reactivity. Yi Zhang; Yeuying Liu; Moxley, Kelly M.; Golden-Mason, Lucy; Hughes Jr, Michael G.; Tongxin Liu; Heemskerk, Mirjam H. M.; Rosen, Hugo R.; Nishimura, Michael I. // PLoS Pathogens;Jul2010, Vol. 6 Issue 7, p1 

    Hepatitis C Virus (HCV) is a major public health concern, with no effective vaccines currently available and 3% of the world's population being infected. Despite the existence of both B- and T-cell immunity in HCV-infected patients, chronic viral infection and HCV-related malignancies progress....

  • Correction.  // Gut;Aug2012, Vol. 61 Issue 8, p1145 

    A correction to the article "New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives," that was published in the previous issue of the journal is presented.

  • New Drug Targets for Hepatitis C and Other Flaviviridae Viruses. Paula, Tuma; Pablo, Rivas; Eugenia, Vispo; Pablo, Barreiro; Sabino, Puente; Jos�, Medrano; Antonio, Madej�n; Dolores, Herrero M.; Pablo, Labarga; Javier, Garcia-Samaniego; Vincente, Soriano Vincente // Infectious Disorders - Drug Targets;Apr2009, Vol. 9 Issue 2, p133 

    The Flaviviridae family comprises the genus Flavivirus, Hepacivirus and Pestivirus. These viruses are responsible for considerable human and animal disease and mortality worldwide. Flaviviruses cause a range of acute febrile illnesses along with encephalitic or haemorrhagic diseases. Chronic...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics